Last reviewed · How we verify
Perampanel Oral Tablet
Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain.
Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain. Used for Adjunctive treatment of partial-onset seizures in patients 12 years of age and older, Adjunctive treatment of primary generalized tonic-clonic seizures in patients 12 years of age and older.
At a glance
| Generic name | Perampanel Oral Tablet |
|---|---|
| Also known as | Fycompa, E2007 |
| Sponsor | University of Arizona |
| Drug class | AMPA receptor antagonist |
| Target | AMPA receptor (GluA1-GluA4) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Perampanel selectively blocks AMPA-type glutamate receptors on the postsynaptic membrane, which are key mediators of excitatory synaptic transmission. By antagonizing these receptors, it reduces neuronal hyperexcitability and abnormal electrical activity associated with seizures. This mechanism differs from other antiepileptic drugs and provides an additional treatment option for patients with inadequate seizure control on existing therapies.
Approved indications
- Adjunctive treatment of partial-onset seizures in patients 12 years of age and older
- Adjunctive treatment of primary generalized tonic-clonic seizures in patients 12 years of age and older
Common side effects
- Dizziness
- Somnolence
- Headache
- Fatigue
- Irritability
- Ataxia
- Aggression
- Weight gain
Key clinical trials
- A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy (PHASE2)
- An Extended Access Program (EAP) for Perampanel
- A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures (PHASE4)
- Effect of Perampanel on Peritumoral Hyperexcitability in HGG (PHASE1, PHASE2)
- Bioequivalence Study of Perampanel Tablets 12 mg (PHASE1)
- Bioequivalence Study of Perampanel Tablets 10 mg (PHASE1)
- Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis (EARLY_PHASE1)
- Perampanel in Focal Status Epilepticus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perampanel Oral Tablet CI brief — competitive landscape report
- Perampanel Oral Tablet updates RSS · CI watch RSS
- University of Arizona portfolio CI